An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase 2 study to assess the safety and effectiveness of a product to treat children and adults with head lice

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr. Reddy's Laboratories Limited; Hatchtech Pty Ltd

Criteria

Inclusion Criteria:

• 2 years of age or older

• Body weight of at least 33 pounds

• Has an active head lice infestation at Day 0. An active infection is defined as at least 3 live lice for the index subject and at least 1 live louse for the other household members

• Belong to a household of no more than 6 members, except where additional household members are < 2 years of age

• Belong to a household with an eligible index subject between 2 and 12 years of age with active lice infestation

• Female subjects must be:

• of non-childbearing potential (no history of menstrual periods, post-hysterectomy, or, post-menopausal for at least 2 years) OR,

• if of childbearing potential, must have a negative urine pregnancy test prior to treatment and agree to use a highly effective method of contraception from Day 0 through the Day 14 visit.

Exclusion Criteria:

• Had treatment for head lice within 14 days prior to Day 0

• Has a household member(s) who is infested with lice but is not willing or not eligible for enrollment

• Has a condition or illness that, in the opinion of the Investigator, may interfere with the study results

• Has an electrocardiographic abnormality, renal disease or impaired renal function, dermatological disease on the face, scalp, ears or neck, or active ophthalmological disease, moderate or severe scleral injection with conjunctival erythema or purulent discharge or allergic or perennial rhinitis requiring chronic treatment

• Has been using hormonal contraception for less than 3 months or is pregnant or lactating

• Has received systemic corticosteroids within 7 days prior to Day 0 or planned while on study

• Receiving systemic or topical medication, which in the opinion of the Investigator, may interfere with the study results

• Has received an investigational agent within 30 days prior to Day 0